Amgen’s Neulasta is set to face its first competition in the US after the FDA approved Mylan’s biosimilar version of the blockbuster cancer infection biologic. Neulasta brought in $4.5 billion ...

As a result Neulasta was still Amgen’s second biggest selling drug last year, with the US accounting for nearly $3.9 billion in sales, with only $609 million coming from the rest of the world.

This leaflet answers some common questions about Neulasta. It does not contain all the available information. It does not take the place of talking to your doctor, nurse or pharmacist. All ...

Cancer patients and survivors are impacted by the financial stress that comes at the price of receiving treatment. ...

Both stocks have been in the limelight lately, given their focus on the lucrative weight-loss treatment market.

Most of the drug delivery revenue consists of sales of Pods to Amgen for use in the Neulasta Onpro kit, an innovative delivery system for Amgen’s white blood cell booster to help reduce the risk ...

The DJIA added Amgen – the maker of Enbrel and Neulasta, which trades around $235 per share currently – in lieu of Pfizer, a massive pharmaceutical by market value, but the Dow's smallest ...

Amgen Inc (NASDAQ:AMGN) has recently announced a dividend of $2.25 per share, set to be payable on June 7, 2024, with the ...

The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant ...

In recent years, Cinfa Biotech used its resources to advance B12019, a biosimilar copy of Amgen’s chemotherapy-induced neutropenia drug Neulasta, through clinical trials. B12019 and Neulasta are ...

Given its better prospects, we believe Eli Lilly stock (NYSE: LLY) is a better pick than Amgen stock (NASDAQ: AMGN). Both stocks have been in the limelight lately, given their focus on the ...